AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Jan 4, 2023
33483_dirs_2023-01-04_c2f32883-118a-4b3a-83ce-5ed672de388f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-01-02
Reporting Person: TRABER PETER G (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-02 | Common Stock | A | 200000 | — | Acquired | 457765 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-02 | Employee Stock Option (right to buy) | $1.13 | A | 900000 | Acquired | 2033-01-01 | Common Stock (900000.0) | Direct |
Footnotes
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027.
F2: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between March 1, 2022 and August 31, 2022.
F3: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.